Page 6 - Peterc Adamson News Today : Breaking News, Live Updates & Top Stories | Vimarsana
FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Sanofi: FDA approves Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival
News provided by
Share this article
TARRYTOWN, N.Y. and PARIS, March 15, 2021 /PRNewswire/
Libtayo is the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer, reducing the risk of death by 31% compared to chemotherapy
Trial enrolled patients with advanced cervical cancer regardless of PD-L1 status
Fourth cancer type where Libtayo has positive pivotal data; first-in-class survival results in cervical cancer follow first-in-class pivotal results in advanced BCC and advanced CSCC
Regulatory submissions planned in 2021
Regeneron Pharmaceuticals, Inc. (NASDAQ:
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early .
SanofiMarch 15, 2021 GMT Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival
Libtayo is the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer, reducing the risk of death by 31% compared to chemotherapy
Trial enrolled patients with advanced cervical cancer regardless of PD-L1 status
Fourth cancer type where Libtayo has positive pivotal data; regulatory submission
Sanofi: Phase 3 trial of Libtayo (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.